|
| Human IL-6 R alpha/CD126 Protein (LTP10533) |
|
| LTP10533 |
|
| 100ug |
|
|
$473 In stock |
| Serum levels of interleukin-6 (IL-6) are increased in patients with type 2 diabetes (T2D). IL-6 exerts its pleiotropic effects via the IL-6 ?-receptor (IL-6R), which exists in membrane-bound and soluble (sIL-6R) forms and activates cells via the ?-receptor glycoprotein 130 (gp130). |
| Recombinant Human IL-6 R alpha/CD126 Protein is expressed from Expi293 with hFc tag at the C-terminal. It contains Leu20-Pro365. |
|
| IL-6 R alpha/CD126 |
|
| Human |
|
| P08887-1 |
|
| Leu20-Pro365 |
|
| The protein has a predicted MW of 65.3 kDa. Due to glycosylation, the protein migrates to 85-110 kDa based on the Tris-Bis PAGE result. |
|
| Immobilized Human IL-6 at 0.5ug/ml (100ul/Well) on the plate. Dose response curve for Human IL-6 R alpha, hFc Tag with the EC50 48.7ng/ml determined by ELISA. See testing image for detail. |
|
| C-hFc |
|
| Expi293 |
|
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
